This second MJFF grant will be used to fund the Company’s CTH-105 clinical study. APL-130277 is an easy-to-administer, fast-acting and proprietary reformulation of apomorphine for sublingual delivery. Injectable
Actavis’ ANDA product is a generic version of Acorda Therapeutics’ Ampyra, which is indicated as a treatment to improve walking in patients with multiple sclerosis. Acorda Therapeutics, Inc.
GelStat acquired 100% of the membership equity in Mastix Medica, LLC in exchange for 27,500,000 restricted shares in GelStat’s common stock. In conjunction with the closing of this
The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen. The milestone being announced today relates to the first
The two companies are partnering to develop a population health management platform solution that leverages CliniWorks’ technologies in disparate data aggregation and Natural Language Processing (which interprets free
The approval makes VIMIZIM the first and only pharmaceutical treatment option available in Canada for children and adults living with this severely debilitating, progressive and life-limiting disorder. "Morquio
Under the terms of the agreement, Mariel acquired the rights to over 450 issued and pending patents, Stryker’s BMP-7-related clinical and research data, and the associated biologic materials.
BGB-290 is an investigational, oral, selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP), an enzyme family which is involved in a number of cellular processes, including DNA
BEMA buprenorphine is being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in
U.S. Patent No. 8,673,292, titled "Pure Populations of Astrocyte Restricted Percursor Cells and Methods for Isolation and Use Thereof," covers the astrocyte family of neural cells of the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.